<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3417a66b-2cf1-29e4-e063-6394a90aba06"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Neomycin and Polymyxin B
  <br/>
         <br/>
Sulfates and Hydrocortisone
  <br/>
         <br/>
Otic Suspension, USP 
 </content>
      <br/>
      <br/>
(Sterile)
</title>
   <effectiveTime value="20250501"/>
   <setId root="83f62c30-39c4-432e-a15b-4b47504b1c13"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3417a983-8124-855a-e063-6294a90af6da"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250501"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-0864" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Neomycin and Polymyxin B Sulfates and Hydrocortisone</name>
                        <formCode code="C60995" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Neomycin sulfate, Polymyxin B Sulfate and Hydrocortisone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="24208-635" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O40UQP6WCF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SULFURIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2225PI3MOV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>THIMEROSAL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="WI4X0X7BPJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCORTISONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="WI4X0X7BPJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCORTISONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="3.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="057Y626693" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NEOMYCIN SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="I16QD7X297" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NEOMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="[USP'U]" value="10000"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19371312D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYMYXIN B SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J2VZ07J96K" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYMYXIN B</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-0864-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20171124"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA064065" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20171124"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38192" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AURICULAR (OTIC)"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_ec657c46-3f8a-4619-ba54-d0bf7d10de39">
               <id root="5ec0e299-23b5-4bef-e053-2991aa0af791"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_f1d2c793-02fd-4836-8246-4303e3bae546">
               <id root="5ec0e299-23b6-4bef-e053-2991aa0af791"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension USP, is a sterile antibacterial and anti-inflammatory suspension for otic use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL contains:</content>
                     <br/>
                     <content styleCode="italics">
                        <content styleCode="bold">ACTIVES:</content>
                     </content>Neomycin Sulfate equivalent to 3.5 mg neomycin base, Polymyxin B Sulfate, equal to 10,000 polymyxin B units, and Hydrocortisone, 10 mg (1%); 
       
 
  <content styleCode="italics">
                        <content styleCode="bold">INACTIVES:</content>
                     </content>Cetyl Alcohol (0.9%), Polysorbate 80, Propylene Glycol, Purified Water. Sulfuric Acid may be added to adjust pH (3.0 - 7.0). 
      

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">PRESERVATIVE ADDED:</content>
                     </content>Thimerosal 0.01%.
      

 </paragraph>
                  <paragraph>Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of 
       
 
  <content styleCode="italics">Streptomyces fradiae </content>Waksman (Fam. Streptomycetaceae). It has a potency equivalent to not less than 600 micrograms of neomycin standard per milligram, calculated on an anhydrous basis. The structural formulae are:
      

 </paragraph>
                  <renderMultiMedia ID="id604694354" referencedObject="ID_4859f30c-756b-4aa0-93fd-44c814e2b478"/>
                  <paragraph>Polymyxin B sulfate is the sulfate salt of polymyxin B
       
 
  <sub>1</sub> and B
       
 
  <sub>2</sub>, which are produced by the growth of 
       
 
  <content styleCode="italics">Bacillus polymyxa</content> (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis. The structural formulae are:
      

 </paragraph>
                  <renderMultiMedia ID="id-712199171" referencedObject="ID_877e9b1c-b257-4b72-8bea-48a93b3b8522"/>
                  <paragraph>Hydrocortisone 11β, 17, 21-trihydroxypregn-4-ene-3,20-dione, is an anti-inflammatory hormone. Its structural formula is:</paragraph>
                  <renderMultiMedia ID="id-788668379" referencedObject="C403261B-070F-4BB8-916E-28D3C3C44806"/>
                  <paragraph>C
       
 
  <sub>21</sub>H
       
 
  <sub>30</sub>O
       
 
  <sub>5</sub>
                  </paragraph>
                  <paragraph>Mol. Wt. 362.46</paragraph>
               </text>
               <effectiveTime value="20171124"/>
               <component>
                  <observationMedia ID="ID_4859f30c-756b-4aa0-93fd-44c814e2b478">
                     <text>C:\Users\dale.iannettie\Documents\SPL Assignments\Neomycin Polymyxin B Sulfates Hydro Otic Suspension\ac11d9b5-9e09-4b36-8e94-e40e18289468-01.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ac11d9b5-9e09-4b36-8e94-e40e18289468-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_877e9b1c-b257-4b72-8bea-48a93b3b8522">
                     <text>C:\Users\dale.iannettie\Documents\SPL Assignments\Neomycin Polymyxin B Sulfates Hydro Otic Suspension\ac11d9b5-9e09-4b36-8e94-e40e18289468-02.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ac11d9b5-9e09-4b36-8e94-e40e18289468-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C403261B-070F-4BB8-916E-28D3C3C44806">
                     <text>C:\Users\dale.iannettie\Documents\SPL Assignments\Neomycin Polymyxin B Sulfates Hydro Otic Suspension\ac11d9b5-9e09-4b36-8e94-e40e18289468-03.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="ac11d9b5-9e09-4b36-8e94-e40e18289468-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_6c242057-f9d3-4b28-aff1-c25151c8b74d">
               <id root="5ec0e299-23b7-4bef-e053-2991aa0af791"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.</paragraph>
                  <paragraph>The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Neomycin sulfate and polymyxin B sulfate together are considered active against the following microorganisms: 
       
 
  <content styleCode="italics">Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter </content>species, 
       
 
  <content styleCode="italics">Neisseria </content>species and 
       
 
  <content styleCode="italics">Pseudomonas aeruginosa</content>. This product does not provide adequate coverage against 
       
 
  <content styleCode="italics">Serratia marcescens </content>and streptococci, including 
       
 
  <content styleCode="italics">Streptococcus pneumoniae</content>.
      

 </paragraph>
                  <paragraph>The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.</paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_5c008679-17f3-45c9-a21c-5432eadbf30b">
               <id root="5ec0e299-23b8-4bef-e053-2991aa0af791"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDlCATlONS AND USAGE</title>
               <text>
                  <paragraph>For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.</paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_c1f2ab11-7c17-4f6e-b93d-c699ebff2b32">
               <id root="5ec0e299-23b9-4bef-e053-2991aa0af791"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.</paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_e6f5ceb7-f190-4af9-bcc4-9042bc538d6e">
               <id root="5ec0e299-23ba-4bef-e053-2991aa0af791"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see 
       
 
  <linkHtml href="#i4i_section_id_c874b855-08ac-4480-bc25-002d01c58e30">PRECAUTIONS</linkHtml> - 
       
 
  <linkHtml href="#i4i_precautions_general_id_6ef2ffdb-040d-4ec5-a899-18f75b328973">General</linkHtml>). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension should not be used in any patient with a perforated tympanic membrane.
      

 </paragraph>
                  <paragraph>Discontinue promptly if sensitization or irritation occurs.</paragraph>
                  <paragraph>Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known.</paragraph>
                  <paragraph>When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifested simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter.</paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_c874b855-08ac-4480-bc25-002d01c58e30">
               <id root="5ec0e299-23bb-4bef-e053-2991aa0af791"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20171124"/>
               <component>
                  <section ID="i4i_precautions_general_id_6ef2ffdb-040d-4ec5-a899-18f75b328973">
                     <id root="5ec0e299-23bc-4bef-e053-2991aa0af791"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General:</title>
                     <text>
                        <paragraph>As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.</paragraph>
                        <paragraph>If the infection is not improved after 1 week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed.</paragraph>
                        <paragraph>Treatment should not be continued for longer than 10 days.</paragraph>
                        <paragraph>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.</paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_info_patients_id_27688bf3-90f3-47d4-8f3b-60f64d603f75">
                     <id root="5ec0e299-23bd-4bef-e053-2991aa0af791"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients:</title>
                     <text>
                        <paragraph>Avoid contaminating the bottle tip with material from the ear, fingers, or other source. This caution is necessary if the sterility of the drops is to be preserved.</paragraph>
                        <paragraph>If sensitization or irritation occurs, discontinue use immediately and contact your physician.</paragraph>
                        <paragraph>Do not use in the eyes.</paragraph>
                        <paragraph>
                           <content styleCode="bold">SHAKE WELL BEFORE USING.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_lab_tests_id_6a345d8d-ac4a-42f1-8fe6-80386218dcea">
                     <id root="5ec0e299-23be-4bef-e053-2991aa0af791"/>
                     <code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION"/>
                     <title>Laboratory Tests:</title>
                     <text>
                        <paragraph>Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_bf441310-5208-4f30-b124-789af6769ec9">
                     <id root="5ec0e299-23bf-4bef-e053-2991aa0af791"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility:</title>
                     <text>
                        <paragraph>Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.</paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_aa3e8beb-09a8-4ba1-9f6c-99f4ce12b47b">
                     <id root="5ec0e299-23c0-4bef-e053-2991aa0af791"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pregnancy:</title>
                     <effectiveTime value="20171124"/>
                     <component>
                        <section ID="i4i_teratogenic_id_738c4959-3e3d-4ceb-a239-0a972ad99f3b">
                           <id root="5ec0e299-23c1-4bef-e053-2991aa0af791"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic effects:</content>
                           </title>
                           <text>
                              <paragraph>Pregnancy Category C. Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20171124"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_70f169d7-6d15-4b01-915c-4796113e3d7a">
                     <id root="5ec0e299-23c2-4bef-e053-2991aa0af791"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers:</title>
                     <text>
                        <paragraph>Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension is used by a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_278c08e4-898d-4128-ac1e-97a53b7f0924">
                     <id root="5ec0e299-23c3-4bef-e053-2991aa0af791"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use:</title>
                     <text>
                        <paragraph>The safety and effectiveness of Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension in otitis externa have been established in the pediatric age group 2 years to 16 years of age. There is inadequate data to establish safety and effectiveness in otitis externa for pediatric patients under 2 years of age.
         
 
  <sup>1</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_b3fee9b8-9e0a-4ee3-b3c4-b34f9635f170">
                     <id root="5ec0e299-23c4-4bef-e053-2991aa0af791"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use:</title>
                     <text>
                        <paragraph>Clinical studies of Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_702a5a02-6a32-461d-99f3-ec289a6c08aa">
               <id root="5ec0e299-23c5-4bef-e053-2991aa0af791"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see 
       
 
  <linkHtml href="#i4i_warnings_id_e6f5ceb7-f190-4af9-bcc4-9042bc538d6e">WARNINGS</linkHtml>). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population.
       
 
  <sup>2</sup> In another study, the incidence was found to be approximately 1%.
       
 
  <sup>3</sup>
                  </paragraph>
                  <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</paragraph>
                  <paragraph>The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear.</paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_7a560ceb-34ea-4208-88a2-a77becc255b6">
               <id root="5ec0e299-23c6-4bef-e053-2991aa0af791"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Therapy with this product should be limited to 10 consecutive days.</paragraph>
                  <paragraph>The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. </paragraph>
                  <paragraph>For adults, 4 drops of the suspension should be instilled into the affected ear 3 to 4 times daily. For infants and children, 3 drops are suggested because of the smaller capacity of the ear canal.</paragraph>
                  <paragraph>The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear.</paragraph>
                  <paragraph>If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours.</paragraph>
                  <paragraph>
                     <content styleCode="bold">SHAKE WELL BEFORE USING.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_d7e95d66-643c-4418-b9de-856aa16a2b9f">
               <id root="2babd410-f618-c6ff-e063-6294a90a389f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension, USP is supplied in a white plastic dropper bottle in the following size:</paragraph>
                  <paragraph/>
                  <paragraph>NDC: 70518-0864-00</paragraph>
                  <paragraph>PACKAGING: 10 mL in 1 BOTTLE, DROPPER </paragraph>
                  <paragraph/>
                  <paragraph>Storage: Store at 15°C to 25°C (59°F to 77°F).</paragraph>
                  <paragraph>FOR USE IN EARS ONLY.</paragraph>
                  <paragraph>DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT</paragraph>
                  <paragraph/>
                  <paragraph>KEEP OUT OF REACH OF CHILDREN.</paragraph>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
               </text>
               <effectiveTime value="20171124"/>
               <component>
                  <section ID="i4i_storage_id_822e36bc-b40e-4502-97ed-4f505d6fbfe4">
                     <id root="5ec0e299-23c8-4bef-e053-2991aa0af791"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>Storage:</title>
                     <text>
                        <paragraph>Store at 15°-25°C (59°-77°F).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Rx only</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">FOR USE IN EARS ONLY</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="underline">DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">KEEP OUT OF REACH OF CHILDREN.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20171124"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_references_id_7282da57-99bf-4d0d-8ea0-1bc61cf90589">
               <id root="2babd410-f619-c6ff-e063-6294a90a389f"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCES</title>
               <text>
                  <list listType="ordered">
                     <item>Jones, RN, Milazzo J, Seidlin, M. Ofloxacin Otic Solution for Treatment of Otitis Externa in Children and Adults. 
   <content styleCode="italics">Arch Otolaryngol Head Neck Surg</content>. 1997; 123: 1193-1200.
  </item>
                     <item>Leyden JJ and Kligman AM. Contact dermatitis to neomycin sulfate. 
   <content styleCode="italics">JAMA</content>. 1979; 242: 1276-1278.
  </item>
                     <item>Prystowsky SD, Allen AM, Smith RW, Nonomura JH, Odom RB, Akers WA. Allergic contact hypersensitivity to nickel, neomycin, ethylenediamine, and benzocaine: relationships between age, sex, history of exposure, and reactivity to standard patch and use tests in a general population. 
   <content styleCode="italics">Arch Dermatol</content>. 1979; 115: 959-962.
  </item>
                  </list>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
               </text>
               <effectiveTime value="20171124"/>
            </section>
         </component>
         <component>
            <section ID="id_link_142cbe38-6d7f-2969-e063-6294a90a4159">
               <id root="3417a906-fa5b-839d-e063-6294a90aa606"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: Neomycin and Polymyxin B Sulfates and Hydrocortisone</paragraph>
                  <paragraph>GENERIC: Neomycin sulfate, Polymyxin B Sulfate and Hydrocortisone</paragraph>
                  <paragraph>DOSAGE: SUSPENSION/ DROPS</paragraph>
                  <paragraph>ADMINSTRATION: AURICULAR (OTIC)</paragraph>
                  <paragraph>NDC: 70518-0864-0</paragraph>
                  <paragraph>PACKAGING: 10 mL in 1 BOTTLE, DROPPER</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>HYDROCORTISONE 10mg in 1mL</item>
                     <item>NEOMYCIN SULFATE 3.5mg in 1mL</item>
                     <item>POLYMYXIN B SULFATE 10000[USP'U] in 1mL</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>CETYL ALCOHOL</item>
                     <item>SULFURIC ACID</item>
                     <item>WATER</item>
                     <item>POLYSORBATE 80</item>
                     <item>PROPYLENE GLYCOL</item>
                     <item>THIMEROSAL</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3417a8dc-ee20-29ea-e063-6394a90a9528"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20171124"/>
               <component>
                  <observationMedia ID="img_3417a8dc-ee20-29ea-e063-6394a90a9528">
                     <text>MM1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Neomycin-Polymyxin B-HC 1_70518-0864-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>